Tumor regression is mediated via the induction of HER263-71-specific CD8+CTL activity in a 4T1.2/HER2 tumor model: no involvement of CD80 in tumor control

In the CT26/HER2 and 4T1.2/HER2 tumor models, CT26/HER2 cells form tumors that continue to grow, whereas 4T1.2/HER2 cells form tumors that eventually regress. Here, we investigated the differences in the behaviors of these two cell lines. When immune cells from 4T1.2/HER2 tumor-bearing animals were stimulated with HER2 class I peptides, they displayed a 2-fold increase in IFN-gamma levels, in response to the peptides, HER2(63-71) and HER2(342-350). In contrast, extremely high levels of antigennon- specific IFN-. production were observed with immune cells and sera from CT26/HER2 tumor-bearing mice. However, IFN-. had no effect on tumor progression in the CT26/HER2 model, as determined by an IFN-. knockout assay. 4T1.2/HER2 tumorbearing mice displayed CTL activity in response to HER263-71 but not to HER2(342-350), whereas no such induction was observed in CT26/HER2 tumor-bearing mice. When 4T1.2/HER2 cell-challenged mice were depleted of CD8+ T cells, they lost their tumorregressing activity, suggesting an antitumor role of HER263-71-specific CD8+ CTLs in the control of this tumor type. CT26/HER2 cells also expressed CD80. However, CD80-transfected 4T1.2/HER2 and CD80-non-expressing CT26/HER2 cells failed to alter their tumorigenicity, suggesting no role of CD80 in tumor control. Despite increased levels of myeloid-derived suppressor cells in the tumor, they were not associated with tumor progression in the CT26/HER2 model, as determined by a cell depletion assay. Overall, these data show that, contrary to CT26/HER2 tumors, 4T1.2/HER2 tumors regress via the induction of HER263-71-specific CD8+ CTLs and that CD80 is not associated with the regression of these tumors.